Abstract
In hormone receptor-positive locally advanced breast cancer, endocrine therapy becomes an integral part of the therapeutic strategy. There are now significant numbers of available hormonal directed compounds, including selective aromatase and mTOR inhibitors, which allow an important therapeutic advance in these patients. Sequential F-FDG PET/CT studies provided essential information regarding response to different treatments, including targeted therapies, and adverse therapeutic effects that helped to better define the right moment to implement each therapeutic approach.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Aromatase Inhibitors / therapeutic use
-
Axilla
-
Bone Density Conservation Agents / therapeutic use
-
Bone Neoplasms / diagnostic imaging*
-
Bone Neoplasms / secondary
-
Breast Neoplasms / diagnostic imaging*
-
Breast Neoplasms / therapy
-
Chemotherapy, Adjuvant
-
Cyclophosphamide / therapeutic use
-
Diphosphonates / therapeutic use
-
Docetaxel
-
Epirubicin / therapeutic use
-
Female
-
Fluorodeoxyglucose F18
-
Fluorouracil / therapeutic use
-
Gonadotropin-Releasing Hormone / analogs & derivatives
-
Humans
-
Imidazoles / therapeutic use
-
Letrozole
-
Lymph Node Excision
-
Lymph Nodes / diagnostic imaging*
-
Mastectomy
-
Multimodal Imaging
-
Neoadjuvant Therapy
-
Neoplasm Staging
-
Nitriles / therapeutic use
-
Positron Emission Tomography Computed Tomography
-
Radiopharmaceuticals
-
Radiotherapy
-
Ribs / diagnostic imaging*
-
Taxoids / administration & dosage
-
Triazoles / therapeutic use
-
Zoledronic Acid
Substances
-
Aromatase Inhibitors
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Nitriles
-
Radiopharmaceuticals
-
Taxoids
-
Triazoles
-
Fluorodeoxyglucose F18
-
Docetaxel
-
Gonadotropin-Releasing Hormone
-
Epirubicin
-
Zoledronic Acid
-
Letrozole
-
Cyclophosphamide
-
Fluorouracil